. Scientific Frontline: What Are Fungal Priority Pathogens? The Rise of Candida auris

Monday, January 30, 2023

What Are Fungal Priority Pathogens? The Rise of Candida auris

A strain of Candida auris cultured in a petri dish at a CDC laboratory.
Photo Credit: Shawn Lockhart / Centers for Disease Control / Public Domain

Scientific Frontline: Extended "At a Glance" Summary: Fungal Priority Pathogens and Candida auris

The Core Concept: Fungal infections represent a significant, increasing, and often deadly threat to global public health, prompting the World Health Organization (WHO) to publish its first-ever list of fungal "priority pathogens," which catalogs the 19 fungi most dangerous to humans.

Key Distinction/Mechanism: While fungal infections traditionally targeted severely ill or immunosuppressed individuals, rising ambient global temperatures are allowing certain deadly fungi, such as the drug-resistant yeast Candida auris, to adapt, overcome mammalian body temperature defenses, and transmit efficiently between humans.

Origin/History: The WHO published its inaugural priority pathogen list in late 2022 to address the severe lack of global research and development funding directed toward fungal treatments; notably, C. auris was completely unknown in human infections prior to 2009.

Major Frameworks/Components:

  • Pathogen Prioritization: The WHO's strategic classification of fungi to direct global attention, specifically categorizing C. auris as a "critical priority" pathogen due to its high mortality rate and rapid global emergence.
  • Climate-Driven Adaptation: The evolutionary hypothesis proposing that as global ambient temperatures rise, fungal species adapt to survive at higher temperatures, circumventing the thermal barrier naturally provided by the normal human body temperature.
  • Nosocomial Transmission: The alarming shift of specific fungi, like C. auris, from opportunistic environmental hazards to pathogens capable of rapid, direct patient-to-patient transmission within healthcare settings, such as intensive care units.

Branches of Science: Medical Microbiology, Infectious Disease Epidemiology, Clinical Mycology, and Public Health.

Future Application: The WHO's prioritization framework is designed to stimulate critically needed government funding, public health resources, and scientific research into novel therapeutic approaches for treating drug-resistant fungal pathogens.

Why It Matters: Fungal pathogens are responsible for at least 13 million infections and 1.5 million deaths globally each year, and without a substantial increase in targeted research, the number of susceptible individuals and deadly clinical outbreaks will continue to accelerate.

Late last year the WHO published a report highlighting the first-ever list of fungal "priority pathogens" – a catalogue of the 19 fungi that represent the greatest threat to public health. The premise behind the publication is both because fungi are a significant and increasing threat to public health and because there is little global R&D into fungi or their treatment.

According to Professor Ana Traven, from the Biomedicine Discovery Institute, fungi can range from the benign (skin and nail infections and vaginal thrush) to the deadly (Candida, Aspergillus), “and they have been largely ignored because deadly fungal infections predominantly target people who are immunosuppressed, they are generally not transmitted in human-to-human contact.”

Then in 2016 a Candida auris infection closed down an ICU in the UK after three deaths, and C. auris was transmitted between patients, something that is rarely seen in fungal infection. C. auris infections didn’t even exist before 2009 in humans, and it is now one of four of the WHO’s “critical priority” pathogens. Professor Traven and her colleague, Dr Claudia Simm have set up the only comprehensive research program in Australia working on C. auris, and are one of only a handful of Australian research teams working on fungal infections at all. “There are fewer scientists working in this space, not because it is not important, it is just not high profile enough,” she said. Less than 5% of NHMRC funding devoted to infectious diseases is given to researchers in the fungal space.  “And when you go to an infectious diseases conference only one in twenty presentations will be on fungal infections,” Dr Simm added. “Which is madness, because fungal pathogens are responsible for at least 13 million infections and 1.5 million deaths globally per year.”

Traditionally fungal infections have targeted severely ill patients and those with reduced function of the immune system. Populations at greatest risk of invasive fungal infections include those with cancer, HIV/AIDS, organ transplants, chronic respiratory disease, patients in intensive care wards.

Now, however, climate change could be broadening the repertoire of these infections, according to Traven. “Normally the body temperature of humans is too high for fungi to grow. But it has been proposed that, as the ambient temperature globally increases, the capacity for fungi to survive at higher temperatures increases” she said.

“Now these infections are breaking down mammal’s body temperature defenses.”

In April last year Traven and Simm published, in a journal published by the American Society for Microbiology, one of the first papers out of Australia on a potential new therapeutic approach for the drug-resistant Candida auris.

“Fungal infections are not going away. We are seeing new serious fungal pathogens emerging and the number of individuals susceptible to these infections is increasing, as we saw for example with mucormycosis (called “black fungus” in the media) in COVID-19 patients last year. There really must be more funding into how these fungi operate and how we can treat them,” Traven said. “Maybe now that the WHO has shone a spotlight on them, there can be action.”

Reference material: What Is: Candida auris

Published in journal: American Society for Microbiology

Title: Disruption of Iron Homeostasis and Mitochondrial Metabolism Are Promising Targets to Inhibit Candida auris

Authors: Claudia Simm, Harshini Weerasinghe, David R. Thomas, Paul F. Harrison, Hayley J. Newton, Traude H. Beilharz, and Ana Traven

Source/Credit: Monash University

Edited by: Scientific Frontline

Reference Number: mcb013023_01

Privacy Policy | Terms of Service | Contact Us